Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia · Delayed Price · Currency is AUD 9.44
+0.07 (0.75%)
Aug 7, 2026, 4:10 PM AEST
Clinuvel Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Clinuvel Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $23.04. The average 1-year stock price forecast is 144.07% higher than the current stock price, while the lowest is $13.00 (+37.71%) and the highest is $40.80 (+332.20%).
Price Target: $23.04 (+144.07%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Clinuvel Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Maintains $40.80 | Buy | Maintains | $40.80 | +332.20% | Jul 29, 2026 |
| Bell Potter | Bell Potter | Buy Maintains $19.00 → $17.00 | Buy | Maintains | $19.00 → $17.00 | +80.08% | May 25, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $32.84 → $27.90 | Buy | Maintains | $32.84 → $27.90 | +195.55% | Mar 2, 2026 |
| Morgans | Morgans | Buy Maintains $13.00 | Buy | Maintains | $13.00 | +37.71% | Feb 27, 2026 |
| MA Financial Group | MA Financial Group | Buy Maintains $23.29 | Buy | Maintains | $23.29 | +146.72% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
99.21M
from 95.02M
Increased by 4.41%
Revenue Next Year
104.60M
from 99.21M
Increased by 5.44%
EPS This Year
0.71
from 0.72
Decreased by -0.84%
EPS Next Year
0.76
from 0.71
Increased by 6.23%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.